Evidence map›Paper›PMID 27815601›Full record

ArticleArchives of toxicology2017

Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.

Marije Strikwold, Bert Spenkelink, Laura H J de Haan, Ruud A Woutersen, Ans Punt, Ivonne M C M Rietjens

Abstract read
In one paragraph

Article in Archives of toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Toxicokinetics in Risk Evaluations.Chemical research in toxicology · 2018
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marije StrikwoldDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands. marije.strikwold@hvhl.nl.ORCID http://orcid.org/0000-0002-7042-4074
Bert SpenkelinkDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Laura H J de HaanDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Ruud A WoutersenDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Ans PuntDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.
Ivonne M C M RietjensDivision of Toxicology, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxicity outcomes derived in vitro do not always reflect in vivo toxicity values, which was previously observed for a series of phenols tested in the embryonic stem cell test (EST). Translation of in vitro data to the in vivo situation is therefore an important, but still limiting step for the use of in vitro toxicity outcomes in the safety assessment of chemicals. The aim of the present study was to translate in vitro embryotoxicity data for a series of phenols to in vivo developmental toxic potency values for the rat by physiologically based kinetic (PBK) modelling-based reverse dosimetry. To this purpose, PBK models were developed for each of the phenols. The models were parameterised with in vitro-derived values defining metabolism and transport of the compounds across the intestinal and placental barrier and with in silico predictions and data from the literature. Using PBK-based reverse dosimetry, in vitro concentration-response curves from the EST were translated into in vivo dose-response curves from which points of departure (PoDs) were derived. The predicted PoDs differed less than 3.6-fold from PoDs derived from in vivo toxicity data for the phenols available in the literature. Moreover, the in vitro PBK-based reverse dosimetry approach could overcome the large disparity that was observed previously between the in vitro and the in vivo relative potency of the series of phenols. In conclusion, this study shows another proof-of-principle that the in vitro PBK approach is a promising strategy for non-animal-based safety assessment of chemicals.

Indexed as

Dose-Response Relationship, DrugModels, TheoreticalAnimalsCaco-2 CellsComputer SimulationEmbryonic DevelopmentEmbryonic Stem CellsFemaleHumansIntestinesMiceMicrosomes, LiverPhenolsPlacentaPregnancyRatsPhenolsAlternative for animal testingEmbryonic stem cell test (EST)In vitro–in vivo extrapolation (IVIVE)Physiologically based kinetic (PBK) modellingReverse dosimetrySubstituted phenols

Identifiers

PMID27815601
PMCPMC5399052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.